RNA News and Research RSS Feed - RNA News and Research

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.
Scientists develop new technique to analyze bacterial populations

Scientists develop new technique to analyze bacterial populations

Scientists from the Icahn School of Medicine at Mount Sinai have developed a new technique to more precisely analyze bacterial populations, to reveal epigenetic mechanisms that can drive virulence. The new methods hold the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens. [More]
Molecular classifications of low-grade gliomas proposed

Molecular classifications of low-grade gliomas proposed

Two research teams have independently proposed molecular classification systems for grade II and III glioma based on three tumour markers, with each category displaying distinct clinical features and outcomes. [More]
Discovery may help scientists attack the root of deadliest brain tumors

Discovery may help scientists attack the root of deadliest brain tumors

Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return. The ability of many brain tumors to regenerate can be traced to cancer stem cells that evade treatment and spur the growth of new tumor cells. [More]
MammaTyper molecular diagnostic test for breast cancer now available in Europe

MammaTyper molecular diagnostic test for breast cancer now available in Europe

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies and its subsidiary BioNTech Diagnostics GmbH, today announced the launch of MammaTyper, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue, for universal use in pathology laboratories. [More]
NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. [More]
Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA). [More]
BioNTech announces launch of MammaTyper test to improve breast cancer treatment

BioNTech announces launch of MammaTyper test to improve breast cancer treatment

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies and its subsidiary BioNTech Diagnostics GmbH, today announced the launch of MammaTyper, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue, for universal use in pathology laboratories. [More]
Researchers receive $10 million grant for citrus greening research project

Researchers receive $10 million grant for citrus greening research project

To help develop a therapeutic treatment for citrus greening disease, a bacterial infection that threatens the future of the U.S. citrus industry, the United States Department of Agriculture Specialty Crop Research Initiative has awarded a diverse group of researchers a $10 million grant. [More]
New UAB research identifies link between temporal lobe epilepsy and memory loss

New UAB research identifies link between temporal lobe epilepsy and memory loss

New research from the University of Alabama at Birmingham identifies an epigenetic cause for why patients with temporal lobe epilepsy tend to have memory loss, and suggests a potential way to reverse that loss. [More]
Finding could help researchers develop new methods to prevent cognitive decline in Alzheimer's disease

Finding could help researchers develop new methods to prevent cognitive decline in Alzheimer's disease

The process that allows our brains to learn and generate new memories also leads to degeneration as we age, according to a new study by researchers at MIT. [More]
Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"). [More]
Steven Schiff wins NIH Director's Pioneer Award to reduce infant deaths from neonatal sepsis

Steven Schiff wins NIH Director's Pioneer Award to reduce infant deaths from neonatal sepsis

Steven Schiff, professor of neurosurgery and Brush Chair Professor of Engineering in Engineering Science and Mechanics, has received a $4.1 million National Institutes of Health Director's Pioneer Award, for research aimed at reducing the number of infant deaths from neonatal sepsis in developing countries by identifying the roots of infection, from season of birth to home environment. [More]
Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Researchers have shown that a novel delivery strategy can efficiently introduce a functional microRNA that has anti-cancer and angiogenic activities into two different types of cells--breast cancer cells to inhibit tumor growth and metastasis, and cells that line blood vessels to protect against atherosclerosis. [More]
The Lancet publishes new Seminar on MERS

The Lancet publishes new Seminar on MERS

Middle East respiratory syndrome (MERS) has recently returned to the headlines as new cases have been exported to Korea and China. Experts are concerned that MERS cases continued to be detected in Saudi Arabia throughout the past year, and there appears to be little reduction in the number of cases since its first discovery three years ago. As the month of Ramadan approaches, with 1 million pilgrims expected to arrive in Saudi Arabia in June and July 2015, MERS remains a threat to global health security. [More]
RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA). [More]
Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel. [More]
UC Santa Cruz-led study offers new insights into molecular mechanisms of biological clock

UC Santa Cruz-led study offers new insights into molecular mechanisms of biological clock

A new study led by UC Santa Cruz researchers has found that a protein associated with cancer cells is a powerful suppressor of the biological clock that drives the daily ("circadian") rhythms of cells throughout the body. [More]
Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML). [More]
Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research. [More]
High CIP2A may guide TKI choice for chronic phase CML

High CIP2A may guide TKI choice for chronic phase CML

Treatment with a second-generation tyrosine kinase inhibitor prevents progression to blast crisis in chronic myeloid leukaemia patients with high levels of cancerous inhibitor of PP2A, research suggests. [More]
Advertisement
Advertisement